Nationwide Fund Advisors Has Decreased By $1.05 Million Its Taro Pharmaceutical (TARO) Holding; Rigel Pharmaceuticals (RIGL) Sentiment Is 0.74

July 17, 2017 - By Vivian Currie

Nationwide Fund Advisors decreased Taro Pharmaceutical (TARO) stake by 68.79% reported in 2016Q4 SEC filing. Nationwide Fund Advisors sold 10,000 shares as Taro Pharmaceutical (TARO)’s stock declined 2.08%. The Nationwide Fund Advisors holds 4,538 shares with $478,000 value, down from 14,538 last quarter. Taro Pharmaceutical now has $4.58 billion valuation. The stock decreased 0.68% or $0.78 on July 14, reaching $113.8. About shares traded. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 13.84% since July 17, 2016 and is downtrending. It has underperformed by 30.54% the S&P500.

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company has market cap of $295.24 million. The Firm is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. It currently has negative earnings. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Nationwide Fund Advisors increased Ciena Corp Common Stock (NYSE:CIEN) stake by 16,230 shares to 390,563 valued at $9.53 million in 2016Q4. It also upped Nike Inc Common Stock (NYSE:NKE) stake by 8,957 shares and now owns 678,748 shares. Pnc Financial Services (NYSE:PNC) was raised too.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on August, 1 after the close. They expect $-0.15 earnings per share, 0.00% or $0.00 from last year’s $-0.15 per share. After $-0.13 actual earnings per share reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.

Ratings analysis reveals 100% of Rigel Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Rigel Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $7.0 while the high is $11.0. The stock’s average target of $9 is 264.37% above today’s ($2.47) share price. RIGL was included in 2 notes of analysts from August 30, 2016. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Overweight” rating by Piper Jaffray on Tuesday, August 30. On Wednesday, August 31 the stock rating was maintained by H.C. Wainwright with “Buy”.

The stock decreased 2.37% or $0.06 on July 14, reaching $2.47. About shares traded. Rigel Pharmaceuticals, Inc. (RIGL) has risen 4.56% since July 17, 2016 and is uptrending. It has underperformed by 12.14% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.